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A key to tapping the potential of iPSCs is the establishment of readily accessible well-characterized panels of
lines for custom screening. Here, we propose a crowdsourcing strategy to rapidly develop a large repository
of iPSCs and provide a model for how the NIH could support this effort.Introduction
The ability to make induced pluripotent
stem cells (iPSCs) from virtually any cell
in the body (Takahashi et al., 2007) repre-
sents a groundbreaking opportunity to
consider novel approaches to drug
screening, disease modeling, and cell-
based therapy (Daley, 2012; Merkle and
Eggan, 2013). In the field of toxicology,
the use of iPSC-derived cardiomyocytes
has already highlighted new paradigms
for evaluating cardiotoxicity, and with
the recent advances in differentiating
hepatocytes, it is likely that further
changes in toxicology screening will
follow (Engle and Puppala, 2013). Like-
wise the ready availability of cell samples
from patients with orphan and rare dis-
eases is laying the groundwork for identi-
fying drugs for therapeutic intervention,
and similarly, the ability to collect cells
with defined cellular or genomic abnor-
malities has allowed the medical field to
consider personalized screens for drug
susceptibility (Lee et al., 2012; Hamburg
and Collins 2010).
What has become clear from these
early studies is that the utility of screening
would be greatly expanded if large panels
of patient-derived lines with defined
mutations along with a detailed family
history were available and if reference
lines and isogenic controls that allowed
identification of disease-associated ge-
netic variants and their contribution to
disease phenotypes were in place.
Making lines and developing the
requisite controls and assays is time
consuming, expensive, and generally
beyond the expertise of any single labora-
tory. These complexities raise concerns
that we may not be able to fully exploit
the potential of iPSCs without radicalchanges in our standard processes of dis-
covery. In this opinion piece we (NHCRM)
propose a crowdsourcing model to obtain
large panels of iPSC lines. Many goals of
this model are being currently imple-
mented by large-scale initiatives aimed
at generating large panels of iPSC lines
for use in academia and pharma, which




the NYSCF initiative (http://www.NYSCF.
org), and the CIRM initiative (http://www.
cirm.ca.gov). However, such programs
rely on substantial continued investment
because each respective organization is
responsible for funding not only the estab-
lishment of the iPSC lines, but also their
maintenance and distribution. These ex-
amples are laudable efforts that we view
as complementary to the approach pro-
posed here. As we will outline below, the
crowdsourcing model would have the
ability to cooperate and capitalize on
such efforts, but would have the addi-
tional benefit of lower long-term funding
costs due to its self-sustaining nature.
Crowdsourcing iPSCs
Crowdsourcing has been a successful
mechanism for building public resources
in a variety of contexts over recent years,
with perhaps the latest high-profile
example being Kickstarter, which is a
crowdsourcing experiment in product
development funding. However, this
model is not new to biologists. The Zebra-
fish Gene Collection, ADDGENE (for
plasmids and constructs), reference
databases such as PubMed, and the
Drosophila ‘‘Red Book’’ are all examples
of collections built up over the years thatCell Stem Cell 1rely on contributions from individual in-
vestigators funded by different grants on
different projects (Ranard et al., 2013;
Kalia, 2013). ADDGENE is an excellent
example of how a crowdsourcing effort
can work. Plasmids generated by inves-
tigators are deposited in a common re-
pository that distributes them to all
academics using a uniform material
transfer agreement (MTA). Given the
success and acceptance of such models
we wondered if crowdsourcing models
could be applied to the rapidly evolving
technology of iPSCs.
It seemed to us that crowdsourcing
iPSCs based on the central establishment
of self-sustaining cell line repositories that
would be populated by multiple individual
labs (Figure 1) should work. Such a model
has a notable economic advantage
because no single stakeholder would
need to foot the entire bill. A governmental
agency or a nonprofit could set up such a
repository. Individual investigators would
work within their own areas of expertise
but would subsequently contribute to the
overall effort by depositing lines to the
repository. In our model, the repository
would utilize its carefully acquired exper-
tise and paid-for infrastructure to store,
expand, and distribute lines, which would
be characterized with a consensus panel
of tests. Individual repositories would
also coordinate with each other to ensure
that panels of lines could be easily assem-
bled, and all stakeholders would work to
ensure that derivatives, subclones, and
new variants developed from the initial
lines would be redeposited to repositories
using the same distribution strategy used
for the original line or lines.
In our view, this redeposit and redistri-














1. Speed: Many labs contribute to eﬀort
2. Cost: Spread over many grants and projects
3. Quality control: Repositories have experience in this arena
4. Reference Material: Widely used lines can serve as a reference 
5. Uniform licensing requirements: NIH has already established dras
6. Custom Panels: Easy to order subsets of lines
7. Common searchable database: Possible to use exisng searchable databases
Possible Advantages
Figure 1. A Possible Crowdsourcing Model for iPSC Access
The schematic represents an outline for a possible crowdsourcing strategy and summarizes the relative
advantages of the model. A key component of the model is that it would be important to include a fee
to cover ongoing costs and redeposition of new lines for the strategy to be self-sustaining.
Cell Stem Cell
Forummaintaining a self-sustaining model
because it would enable panel expansion
and continuous repository updates. To
ensure that the repository would recover
its operating costs, the repositories could
charge a modest usage fee. This nominal
charge would circumvent the need for
a long-term commitment from funding
agencies (but not the initial set-up costs).
Another potential caveat to consider
would be the possibility that technology
patent and license holders could raise
roadblocks that would disrupt wide-
spread distribution of the lines. However,
one can turn to the example of ADDGENE
as a promising example where patent
holders have not caused undue interfer-
ence. This type of behavior would be crit-
ical for maintaining reasonable user costs.
In addition, a graded price model with
differential industry versus academic
usage fees could be considered as a
means of encouraging patent and license
holders to engage in such nonobstruc-
tionist behavior. This type of graded
pricing model would likely encourage a
more seamless transition from academia
to industry, thereby promoting broader
usage of the repository lines by reducing
the divide between what academia uses
and what Pharma uses.
It is important to note that the size of the
repositories would likely impact their abil-390 Cell Stem Cell 13, October 3, 2013 ª201ity to meet the demands of the iPSC mar-
ket. If a repository was sufficiently large, it
could accommodate rarely used lines
without rendering them too expensive for
use. Akin to the strategy used by the
mouse model community, rare samples
would not be kept in stock but would be
generated on demand if necessary. While
this strategy would translate into an end-
user delay, it would nevertheless assure
availability. Users have historically been
satisfied with this arrangement. Such a
combination model with rapid distribution
of most lines and a delayed distribution of
rarely used lines would not require any
major upgrades to the distribution capac-
ities that currently exist at repositories.
Likewise, in terms of capacity, while it is
likely that no single repository would be
able to accommodate all the lines that
are being proposed, the aggregated ca-
pacity would be sufficient.
NIH, the Promise of Personalized
Medicine, and Crowdsourcing
Although implementing such a program
seems feasible, it will likely require a
jumpstart by some entity, and the efforts
of the various repositories would need to
be coordinated. Although any large stake-
holder, such as a private foundation, re-
pository or industry association, or even
a company, could take the lead, we feel3 Elsevier Inc.that the NIH may perhaps be the ideal en-
tity to initially establish the necessary
infrastructure (Figure 2). The NIH has his-
torically taken such a leadership role, it is
widely perceived as a neutral stakeholder,
and in the US it is the largest funder of
iPSC line generation (as with other sci-
ence). In addition, it is likely that many of
the technologies incorporated into cell
line generation would have been devel-
oped by NIH-funded scientists. The NIH,
as part of Dr. Collins’ vision of 21st century
medicine, has already set up the National
Center for Advanced Translational Sci-
ence (NCATS) and the NIH Center for
Regenerative Medicine (NIHCRM) and
challenged the NIH to develop novel
ways of responding to the changing med-
ical research environment (Brewer, 2009;
Prebula, 2010; Hamburg and Collins
2010). It seemed to us that developing
such a crowdsourcing model would sup-
port these current efforts. Although the
NIH has funded the generation of more
than 10,000 lines through various Institute
initiatives, there has been no central plan
to support the deposition and distribution
of lines. In this case, developing such
infrastructure would be critical for suc-
cess and represents a key challenge for
this project.
In order for this model to be successful,
however, it must be self-sustaining. Tech-
nology holdersmust buy in to the idea that
it will ultimately benefit them aswell as the
users. It would also be important to
ensure that expertise existed in the
various repositories to store, charac-
terize, test, and track the cells and their
derivatives and that the repositories could
do so at costs that were reasonable for
the end user.
Over the past 2 years NHCRM has suc-
ceeded in putting all the pieces together.
These steps included generating a few
key lines, characterizing them, and
depositing them with at least one reposi-
tory. We made the lines available to
service providers and pharma collabora-
tors and ensured buy-in from the patent
and license holders. While we have been
encouraged by the positive response we
have received, only time will tell if this
test model will work. Our discussions
with various stakeholders thus far have
been positive. Most notably, several
groups that are currently involved in
similar large-scale efforts to generate














1. Arranges agreements with repositories
2. Jumpstarts program by deposing lines
3. Arranges LULLS with patent and technology holders
4. Develops appropriate consent forms to allow deposit and distribuon
5. Works with repositories to ensure quality control and cost
6. Develops agreements with other other instutes to deposit lines
7. Iniates agreements 
8. Redeposits engineered subclones
Responsibilies for NIHCRM
with service providers for distributed lines
Figure 2. The NIHCRM Execution Strategy
TheNIH can play a key role at various stages of generating an implementing the iPSC crowdsourcing strat-
egy, including (1) jumpstarting the strategy by providing initial funding and initial deposit of lines, (2) enforc-
ing regulations, and (3) acting as an honest broker between various stakeholders.
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port for the crowdsourcing model and
indicated that they would participate in
coordinated efforts to ensure that refer-
ence or control lines are shared to allow
generation of panels that cross repository
boundaries. We look forward to hearing
from readers about their initial experience
and their suggestions for moving forward,
scaling up to meet our goals, and how we
should measure success.
How Will We Know if It Works?
As with any experiment one needs to
define success and develop ways tomea-
sure it. In our case we have considered
two different measures to evaluate perfor-
mance. First, fromapractical stance, does
the program, once established, effectively
obtain and distribute a wide share of iPSC
lines? Second, and perhaps a more
rigorous assessment, does this model
work better than alternative models, i.e.,
is it better, cheaper, or faster?
The first measure of success seems
relatively straightforward, and potential
parameters for assessment are summa-
rized in Table S1. If scientists embrace
thismodel, repositories agree to distribute
lines, and the patent holders agree, then
we will know that the model is feasible.
The academics, service providers, andpharmaceutical companies that use the
lines will provide information about the
extent of success achieved. If the govern-
ment or a central funding agency does not
have to directly sustain the repositories,
their self-sustaining capacity can be taken
as an additional criterion of success. In the
long term, perhaps the entry of commer-
cial or noncommercial competitors could
also be viewed as a measure of success.
The announcement by three repositories
(Rutgers, Coriell, and WISC) that they will
establish banks and accept deposits, fol-
lowed by the more recent announcement
by Cellectis that they are establishing
a private bank (https://www.sceil.com/
our-program), all suggest that iPSC
banking is a clear need. Perhaps an early
indicator that crowdsourcing as a model
maybe apromising approach is the recent
announcement by Sigma that they will
establish a bank for engineered ZFN lines
that will largely hew to the crowdsourcing
model we describe above. The other
major outstanding question is whether
crowdsourcing will be successful as an
alternative to a centrally funded, govern-
ment-run project or a private market
enterprise driven by a profit model. There
is considerable discussion about such
central models, and indeed, the US gov-
ernment, state governments, the EU,Cell Stem Cell 1Japan, and other large funding agencies
are all considering such initiatives. Time
will tell if this crowdsourcing experiment
will survive, thrive, or wither. Our predic-
tion is that multiple models will thrive
alongside each other, with niche markets
being dominated by one or the other
model as has been the case in most in-
stances. However, in each case where
crowdsourcing is used, it has had a signif-
icant impact on price and availability, and
if that is the case then this example will
certainly have been a success.SUPPLEMENTAL INFORMATION
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